These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17595893)

  • 1. Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
    Hong EH; Kim MY; Park JE; Lee MH; Oh JM; Shin WG
    Int J Clin Pharmacol Ther; 2007 Jun; 45(6):355-65. PubMed ID: 17595893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
    JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.
    Ge J; Han Y; Jiang H; Sun B; Chen J; Zhang S; Du Z;
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):162-6. PubMed ID: 16044027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
    Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
    N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.